ArticleFrontiers in pharmacology2026
Factors influencing adverse reactions to adrenocorticotropic hormone treatment in infantile epileptic spasm syndrome: a single-center retrospective study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Infantile Epileptic Spasm Syndrome (IESS) is a rare and severe developmental epileptic encephalopathy. Adrenocorticotropic hormone (ACTH) is regarded as one of the three major first-line treatment for IESS. However, the factors associated with the occurrence of adverse reactions during ACTH therapy remain unclear. This study aimed to identify and evaluate the clinical factors associated with the occurrence of adverse events (AEs) in patients with IESS undergoing ACTH therapy. Methods: This retrospective case-control study included 94 patients with IESS who received ACTH therapy in Shanghai between March 2015 and November 2024. Cases were defined as those who developed clinical AEs. Propensity score matching was employed to minimize potential confounding factors. Association between potential risk factors and AEs were evaluated using the Mann-Whitney U tests and Spearman's correlation analysis. Results: Among the study cohort, 24 cases did not experience any AEs. Overall, patients with AEs were associated with a longer duration of ACTH treatment (13.34 vs. 11.79 days, p = 0.074) and a higher total cumulative dose (367.20 vs. 300.29 IU, p = 0.088). In subgroup analyses, respiratory system AEs showed no significant correlation with treatment duration or the cumulative dose. In contrast, the occurrence of hypertension was significantly associated with the daily average dose (25.53 vs. 1.81 IU/day, p = 0.021), the initial dose (22.12 vs. 9.29IU, p < 0.001) and initial average dose (2.73 vs. 1.21 IU/kg, p < 0.001) of ACTH. Conclusion: Both the duration and cumulative dose of ACTH therapy are positively correlated with the incidence of AEs. The risk of hypertension during ACTH treatment for IESS is significantly linked to the initial dosing of ACTH. Careful consideration should be given to the selection of the initial ACTH dosage before initiating treatment for IESS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.